Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1CNS 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 136Lenalidomide 79daratumumab 77Bortezomib 66pomalidomide 48Cyclophosphamide 48carfilzomib 43Calcium Dobesilate 42Specimen Handling 35Biopsy 32Magnetic Resonance Spectroscopy 29belantamab mafodotin 26fludarabine 23isatuximab 22iberdomide 19dexamethasone acetate 19dexamethasone 21-phosphate 19auricularum 19Melphalan 18talquetamab 17fludarabine phosphate 14elotuzumab 12selinexor 11X-Rays 10tocilizumab 9Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Crizotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pharmaceutical Preparations × Plasma cell × 90 days × Clear all
NCT05889221 2026-04-30

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Poitiers University Hospital

Phase NA Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Peking University People's Hospital

Recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡